PDgrastim® contains G-CSF (Filgrastim), a colony stimulating factor.
PDgrastim® is supplied as 300µg filgrastim in a 0.5 mL prefilled syringe and ampoule for subcutaneous (SC) injection.
PDgrastim® is used for reduction the risk of infection in patients receiving strong chemotherapeutic agents.
PDgrastim® is used for neutropenia treatment.
PDgrastim® is a man-made form of granulocyte colony-stimulating factor (GCSF), which is produce using the bacteria E coli. G-CSF is a substance naturally produced by the body. It stimulates the growth of neutrophils.
Granulocyte colony-stimulating factor; acts on hematopoietic cells by binding to specific cell surface receptors which regulates the production and release of functional neutrophils from the bone marrow.
PDgrastim® Clearance has been shown to follow first-order pharmacokinetics after subcutaneous and administration.
PDgrastim® elimination half-life: approximately 3.5 hours
- Cancer Patients Receiving Myelosuppressive Chemotherapy
- Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy
- Cancer Patients Receiving Bone Marrow Transplant
- Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy
- Patients With Severe Chronic Neutropenia
- mobilisation of peripheral blood progenitor cells (PBPCs)
- increase neutrophil counts and reduce the incidence and duration of infection-related events In patients with severe congenital, cyclic, or idiopathic neutropenia and a history of severe or recurrent infections
- treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/l) in patients with advanced HIV infection
Serious side effects:
Spleen rupture, serious allergic reactions, acute respiratory distress syndrome
Most common side effects:
Bone and muscle aching, injection site reactions (redness, swelling or aching), Headache, Fatigue
Drugs such as lithium may potentiate the release of neutrophils; patients receiving lithium and PDgastrim® should have more frequent monitoring of neutrophil counts.
- CBC with differential and platelets prior to treatment and periodically during the treatment
- In congenital neutropenia monitor Bone marrow and karyotype prior to treatment; and monitor marrow and cytogenetics annually throughout treatment